← Back to Search

Device

1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAA for Sickle Cell Disease

N/A
Waitlist Available
Led By Boris Stoeber
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

This trial evaluates low-cost screening techniques to detect sickle cell disease, sickle cell trait, and β-thalassaemia in remote/rural settings, to reduce mortality rate and improve quality of life.

Eligible Conditions
  • Sickle Cell Disease
  • Sickle Cell-Beta Thalassemia
  • Beta Thalassemia
  • Sickle Cell Trait

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sensitivity, specificity, positive predictive value and negative predictive value

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1) HbSS; 2) HbAS; 3) HbS/β-thalassemia; 4)Hbβ/β-thalassemia; 5) HbA/β- thalassemia; 6) HbAAExperimental Treatment6 Interventions
Around 20 participants each (in Nepal): with the homozygous form of sickle cell disease (HbSS) with the heterozygous form of sickle cell disease (HbAS) with the compound heterozygous form of sickle cell disease (HbS/β-thalassemia) with the carrier form of β-thalassemia (HbA/β-thalassemia) with the carrier form of β-thalassemia (HbA/β-thalassemia) without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc. Around 30 participants each (in Canada): with the homozygous form of sickle cell disease (HbSS) with the heterozygous form of sickle cell disease (HbAS) without any known hemoglobin disorders, such as sickle cell disease, sickle cell trait, β-thalassemia, etc.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Automated sickling test
2022
N/A
~140
Sickle SCAN
2022
N/A
~140
HbS solubility test
2022
N/A
~140
High performance liquid chromatography
2022
N/A
~140
Gazelle Hb Variant Test
2022
N/A
~140
HemoTypeSC
2022
N/A
~140

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,415 Previous Clinical Trials
2,466,878 Total Patients Enrolled
Boris StoeberPrincipal InvestigatorUniversity of British Columbia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still room for additional participants in this clinical trial?

"Per the data on clinicaltrials.gov, this medical trial is presently looking to enroll patients with an initial post-date of September 20th 2022 and a most recent update occurring November 1st 2022."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
Boris Stoeber 2022. "Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05506358.
~53 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top